BS50 Stock Overview
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Inotiv, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.90 |
| 52 Week High | US$10.10 |
| 52 Week Low | US$1.53 |
| Beta | 3.2 |
| 1 Month Change | -40.91% |
| 3 Month Change | 19.63% |
| 1 Year Change | -26.42% |
| 3 Year Change | -82.11% |
| 5 Year Change | 120.71% |
| Change since IPO | 16.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| BS50 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 5.4% | -0.7% | -1.0% |
| 1Y | -26.4% | -14.6% | 2.0% |
Return vs Industry: BS50 underperformed the German Life Sciences industry which returned -14.6% over the past year.
Return vs Market: BS50 underperformed the German Market which returned 2% over the past year.
Price Volatility
| BS50 volatility | |
|---|---|
| BS50 Average Weekly Movement | 18.2% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BS50's share price has been volatile over the past 3 months.
Volatility Over Time: BS50's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 2,005 | Bob Leasure | www.inotivco.com |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company’s BASi product line.
Inotiv, Inc. Fundamentals Summary
| BS50 fundamental statistics | |
|---|---|
| Market cap | €102.30m |
| Earnings (TTM) | -€30.84m |
| Revenue (TTM) | €543.57m |
0.2x
P/S Ratio-3.3x
P/E RatioIs BS50 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BS50 income statement (TTM) | |
|---|---|
| Revenue | US$585.17m |
| Cost of Revenue | US$411.75m |
| Gross Profit | US$173.43m |
| Other Expenses | US$206.63m |
| Earnings | -US$33.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 29.64% |
| Net Profit Margin | -5.67% |
| Debt/Equity Ratio | 149.3% |
How did BS50 perform over the long term?
See historical performance and comparison